Array Biopharma (NASDAQ: ARRY) reported Q3 EPS of ($0.11), $0.11 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $66.4 million versus the consensus estimate of $31.67 million.

For earnings history and earnings-related data on Array Biopharma (ARRY) click here.